论文部分内容阅读
目的了解抗结核固定剂量复合剂治疗初治肺结核患者依从性情况。方法将病例分为抗结核FDC治疗组和板式组合药对照组,均采用问卷调查的形式,于治疗前、强化期末和疗程结束后就有关抗结核依从性问题询问患者,并进行记录。结果治疗前表示能够坚持服用6~8个月的比例FDC组与板式组合药组差异无统计学意义(P>0.05),愿意隔日服药的比例FDC组大于板式组合药组(P<0.05);强化期末能够坚持按医生服药的比例FDC组大于板式组合药组(P<0.05),感觉药片太大的比例FDC组大于板式组合药组(P<0.05),感觉药片数量太多的比例FDC组小于板式组合药组(P<0.05),感觉服药无困难的比例FDC组大于板式组合药组(P<0.05),表示能够再坚持4个月治疗的比例FDC组大于板式组合药组(P<0.05);疗程末坚持按医生服药的比例FDC组大于板式组合药组(P<0.05),FDC组与板式组合药组感觉服药难受均主要见于前2个月(P>0.05)。结论抗结核FDC治疗初治肺结核能提高患者的依从性,可作为一种新型制剂替代板式组合药。
Objective To understand the compliance of anti-tuberculosis fixed-dose combination in the treatment of newly diagnosed pulmonary tuberculosis patients. Methods The cases were divided into the anti-tuberculosis FDC treatment group and the plate-shaped combination medicine control group. Questionnaires were taken and recorded before the treatment, at the end of the intensive period and after the end of the course of treatment on the anti-TB compliance. Results There was no significant difference between the FDC group and the plate combination group (P> 0.05). The proportion of FDC group that was willing to take the next day was higher than that of the plate combination group (P <0.05). (P <0.05). The ratio of FDC group to FDC group (P <0.05) was higher than that of plate combination group (P <0.05), the proportion of feeling FDC group was larger than that of plate combination group (P <0.05) (P <0.05), and the proportion of FDC patients who felt no difficulty in taking FDC group was higher than that of plate combination group (P <0.05), indicating that the proportion of FDC group that can be treated for 4 months was greater than that of plate combination group (P < 0.05). At the end of the course of treatment, the proportion of patients who insisted on taking drugs by doctors was greater than that of plate-shaped combination drugs (P <0.05). The uncomfortable feeling of patients taking FDC and plate-shaped combination drugs was mainly seen in the first 2 months (P> 0.05). Conclusion The anti-tuberculosis FDC can improve the compliance of patients with primary pulmonary tuberculosis and can be used as a new alternative to plate-based combination medicine.